Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

Phase 1 Completed 22 enrolled Syntrix Biosystems, Inc. National Institute of Allergy and Infectious Diseases (NIAID) · collab

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the safety and pharmacokinetic properties (the absorption, distribution and excretion) of two preparations of aminopterin (0.25 mg tablets and 1.0 mg tablets) following oral administration by subjects with moderate to severe psoriasis.

Timeline

Start: 2009-06
Primary completion: 2010-04
Completion: 2010-04

Publications

Menter A, Thrash B, Cherian C, Matherly LH, Wang L, Gangjee A, Morgan JR, Maeda DY, Schuler AD, Kahn SJ, Zebala JA. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J Pharmacol Exp Ther. 2012 Sep;342(3):696-708. doi: 10.1124/jpet.112.195479. Epub 2012 May 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	aminopterin	Small molecule	0.25 mg	Oral
Comparator	aminopterin	Small molecule	1 mg	Oral

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

Summary

Timeline

Publications

Drugs

Indications